At the news
? BEARISHIMPACT 7/10 8-K filed Aug 10, 2026 at 07:15 ET
Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719 failed to meet its key activity endpoint (sweat chloride reduction, p=0.7), and the company is not advancing SION-719 as an add-on to standard of care. The Phase 1 dual-combination trial achieved PK/safety objectives and identified SION-451+SION-2222 as the preferred combination, but next steps are being evaluated as the company plans to preserve capital. This is a material pipeline setback for a clinical-stage biopharma with a $2.3B market cap, significantly de-risking its lead program.
- Phase 2a PreciSION CF trial of SION-719 did not meet its key activity endpoint: -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7)
- Company is not advancing SION-719 as an add-on to standard of care
- Phase 1 trial of SION-451 dual combinations met safety, tolerability, and PK objectives; SION-451 + SION-2222 identified as preferred dual combination
- Company ended Q2 2026 with approximately $268.3 million in cash and intends to take actions to preserve capital while evaluating next steps for the SION-451 program
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access